Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) Global Phase 2b/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results